

Programme	Indication	Preclinical	Phase 1	Phase 2
▶ Amlitelimab (anti-OX40L)	Atopic Dermatitis	▶		
▶ Amlitelimab (anti-OX40L)	Other Immune Disorders	▶		
▶ Alomfilimab (anti-ICOS)	Solid Tumours	▶		
▶ Alomfilimab (anti-ICOS) + anti-PD-L1	Solid Tumours	▶		
▶ KY1070 (anti-BMP6)	Anaemia of chronic inflammation	▶		
▶ KY1051 (anti-CXCR4)	Solid Tumours	▶		